Empagliflozin in Heart Failure Dialysis Patients

Summary

Empagliflozin is not still approved for glomerular filtration rate \< 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.

Timeline

Start

2023-06-01

Primary completion

2025-06-01

Completion

2025-06-03

Drugs

Indications